رجوع

Chugai Pharmaceutical Co., Ltd.

جودة البيانات: 100%

CHGCF

OTC Healthcare Drug Manufacturers - General

KWD 51.94

▼ KWD 0.30 (-0.58%)

القيمة السوقية: 85.48B

مُدرج أيضًا باسم CHGCY OTC

نطاق اليوم

KWD 51.94 KWD 64.01

نطاق 52 أسبوعًا

KWD 38.76 KWD 72.30

حجم التداول

216

متوسط 50 يوم / 200 يوم

KWD 58.19 / KWD 51.05

الإغلاق السابق

KWD 52.24

تاريخ السعر

الاتجاهات المالية

مقارنة الأقران

مقابل وسيط قطاع Healthcare (626 نظير)

المقياس	السهم	وسيط القطاع
P/E	0.2	0.4
P/B	0.0	2.9
ROE %	22.1	3.7
Net Margin %	34.5	3.8
Rev Growth 5Y %	5.9	10.0
D/E	0.0	0.2

النقاط الرئيسية

Revenue grew 5.93% annually over 5 years — modest growth

ROE of 22.11% indicates high profitability

Net margin of 34.50% shows strong profitability

Debt/Equity of 0.00 — conservative balance sheet

Generating 313.45B in free cash flow

P/E of 0.20 — trading at a low valuation

النمو

Revenue Growth (5Y)

5.93%

Revenue (1Y)7.55%

Earnings (1Y)12.15%

FCF Growth (3Y)-3.37%

الجودة

Return on Equity

22.11%

ROIC21.85%

Net Margin34.50%

Op. Margin46.92%

الأمان

Debt / Equity

0.00

Current Ratio4.23

Interest Coverage575.24

التقييم

P/E Ratio

0.20

P/B Ratio0.04

EV/EBITDA-0.58

Dividend Yield0.02%

All Fundamental Metrics

Growth
Revenue Growth (1Y)	7.55%	Revenue Growth (3Y)	6.44%
Earnings Growth (1Y)	12.15%	Earnings Growth (3Y)	15.53%
Revenue Growth (5Y)	5.93%	Earnings Growth (5Y)	9.42%
Profitability
Revenue (TTM)	1.26T	Net Income (TTM)	434.39B
ROE	22.11%	ROA	17.58%
Gross Margin	71.09%	Operating Margin	46.92%
Net Margin	34.50%	Free Cash Flow (TTM)	313.45B
ROIC	21.85%	FCF Growth (3Y)	-3.37%
Safety
Debt / Equity	0.00	Current Ratio	4.23
Interest Coverage	575.24	Dividend Yield	0.02%
Valuation
P/E Ratio	0.20	P/B Ratio	0.04
P/S Ratio	0.07	PEG Ratio	2.68
EV/EBITDA	-0.58	Dividend Yield	0.02%
Market Cap	85.48B	Enterprise Value	-341.50B

Income Statement

Annual, most recent first

Income statement data, annual, most recent first
Metric	FY2025	FY2024	FY2023	FY2022	FY2021
Revenue	1.26T	1.17T	1.11T	1.26T	999.76B
Net Income	434.39B	387.32B	325.47B	374.43B	303.00B
EPS (Diluted)	263.95	235.36	197.80	227.57	184.17
Gross Profit	895.03B	831.20B	698.06B	783.70B	661.61B
Operating Income	590.71B	542.00B	439.17B	533.31B	421.90B

Balance Sheet

Annual, most recent first

Balance sheet data, annual, most recent first
Metric	FY2025	FY2024	FY2023	FY2022	FY2021
Total Assets	2.47T	2.21T	1.93T	1.87T	1.54T
Total Liabilities	443.25B	306.87B	306.97B	445.37B	350.68B
Shareholders' Equity	2.03T	1.90T	1.63T	1.42T	1.19T
Total Debt	0.0	10.90B	13.46B	14.11B	16.04B
Cash & Equivalents	426.97B	540.20B	458.67B	222.17B	267.75B
Current Assets	1.74T	1.61T	1.37T	1.34T	1.06T
Current Liabilities	411.44B	290.36B	288.22B	423.73B	327.42B

درجات الاستراتيجيات

This stock passed the criteria for 5 strategies

Score = fit strength (0–100)

Rank = position among all matches

Custom Capital Light Compounder

#47 of 213

Custom Deep Value Investing (Seth Klarman)

#511 of 820

Custom Contrarian Investing (David Dreman)

#527 of 658

Value Defensive Investing (Benjamin Graham)

#637 of 708

Value Value Investing (Warren Buffett)

#183 of 195

النشاط الأخير

دخل Deep Value Investing (Seth Klarman)

Mar 24, 2026

دخل Capital Light Compounder

Mar 24, 2026

دخل Contrarian Investing (David Dreman)

Mar 24, 2026

دخل Defensive Investing (Benjamin Graham)

Mar 24, 2026

دخل Value Investing (Warren Buffett)

Mar 24, 2026